M
Michela Perego
Researcher at Wistar Institute
Publications - 27
Citations - 2468
Michela Perego is an academic researcher from Wistar Institute. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 14, co-authored 20 publications receiving 1628 citations.
Papers
More filters
Journal ArticleDOI
Myeloid-derived suppressor cells coming of age.
TL;DR: The origin and nature of myeloid-derived suppressor cells, as well as their distinctive features and biological roles in cancer, infectious diseases, autoimmunity, obesity and pregnancy are discussed.
Journal ArticleDOI
LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.
Chiara Camisaschi,Chiara Casati,Francesca Rini,Michela Perego,Annamaria De Filippo,Frédéric Triebel,Giorgio Parmiani,Filiberto Belli,Licia Rivoltini,Chiara Castelli +9 more
TL;DR: Ex vivo analysis showed that CD4+CD25highFoxp3+LAG-3+ T cells are functionally active cells that release the immunosuppressive cytokines IL-10 and TGF-β1, but not IL-2.
Journal ArticleDOI
Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation
Yumei He,Yumei He,Xing Li,Xing Li,Michela Perego,Yulia Nefedova,Andrew V. Kossenkov,Erik A. Jensen,Valerian E. Kagan,Yu-Feng Liu,Shuyu Fu,Qing-Jian Ye,Yan-Hong Zhou,Lai Wei,Dmitry I. Gabrilovich,Dmitry I. Gabrilovich,Dmitry I. Gabrilovich,Jie Zhou,Jie Zhou,Jie Zhou +19 more
TL;DR: The transitory presence of MDSCs may be critical for regulation of inflammation in newborns and played a critical role in control of experimental necrotizing enterocolitis in newborn mice.
Journal ArticleDOI
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
Rajasekharan Somasundaram,Gao Zhang,Mizuho Fukunaga-Kalabis,Michela Perego,Clemens Krepler,Xiaowei Xu,Christine Wagner,Denitsa Hristova,Jie Zhang,Tian Tian,Zhi Wei,Qin Liu,Kanika Garg,Johannes Griss,Rufus Hards,Margarita Maurer,Christine Hafner,Marius Mayerhöfer,Georgios Karanikas,Ahmad Jalili,Verena Bauer-Pohl,Felix Weihsengruber,Klemens Rappersberger,Josef Koller,Roland Lang,Courtney W. Hudgens,Guo Chen,Michael T. Tetzlaff,Lawrence Wu,Dennie T. Frederick,Richard A. Scolyer,Georgina V. Long,Manashree Damle,Courtney Ellingsworth,Leon Grinman,Harry Choi,Brian J. Gavin,Margaret C. Dunagin,Arjun Raj,Nathalie Scholler,Nathalie Scholler,Laura Gross,Marilda Beqiri,Keiryn L. Bennett,Ian R. Watson,Helmut Schaider,Michael A. Davies,Jennifer A. Wargo,Brian J. Czerniecki,Lynn M. Schuchter,Dorothee Herlyn,Keith T. Flaherty,Meenhard Herlyn,Stephan N. Wagner +53 more
TL;DR: A mechanism of acquired drug resistance through the tumor microenvironment, which is mediated by human tumor-associated B cells-derived IGF-1 is described, with important clinical implications in melanoma patients.
Journal ArticleDOI
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
Clemens Krepler,Katrin Sproesser,Patricia Brafford,Marilda Beqiri,Bradley Garman,Min Xiao,Batool Shannan,Andrea Watters,Michela Perego,Gao Zhang,Adina Vultur,Xiangfan Yin,Qin Liu,Ioannis N. Anastopoulos,Bradley Wubbenhorst,Melissa Wilson,Wei Xu,Giorgos C. Karakousis,Michael Feldman,Xiaowei Xu,Ravi K. Amaravadi,Tara C. Gangadhar,David E. Elder,Lauren E. Haydu,Jennifer A. Wargo,Michael A. Davies,Yiling Lu,Gordon B. Mills,Dennie T. Frederick,Michal Barzily-Rokni,Keith T. Flaherty,Dave S.B. Hoon,Michael J. Guarino,Joseph J. Bennett,Randall W Ryan,Nicholas J. Petrelli,Carol L. Shields,Mizue Terai,Takami Sato,Andrew E. Aplin,Alexander Roesch,David B. Darr,Steve Angus,Rakesh Kumar,Ensar Halilovic,Giordano Caponigro,Sébastien Jeay,Jens Wuerthner,Annette O. Walter,Matthias Ocker,Matthew B. Boxer,Lynn M. Schuchter,Katherine L. Nathanson,Meenhard Herlyn +53 more
TL;DR: This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-responders to immune checkpoint blockade, and 31 samples from brain metastasis, and shows examples of pre-clinical trials that highlight how the PDX collection can be used to develop and optimize precision therapies, biomarkers of response, and the targeting of rare genetic subgroups.